JPH09509046A - トランスジェニックマウス - Google Patents
トランスジェニックマウスInfo
- Publication number
- JPH09509046A JPH09509046A JP7515252A JP51525294A JPH09509046A JP H09509046 A JPH09509046 A JP H09509046A JP 7515252 A JP7515252 A JP 7515252A JP 51525294 A JP51525294 A JP 51525294A JP H09509046 A JPH09509046 A JP H09509046A
- Authority
- JP
- Japan
- Prior art keywords
- yac
- mutation
- mouse
- human
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011830 transgenic mouse model Methods 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 66
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 53
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 30
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 22
- 210000000130 stem cell Anatomy 0.000 claims abstract description 18
- 230000009261 transgenic effect Effects 0.000 claims abstract description 13
- 210000001671 embryonic stem cell Anatomy 0.000 claims abstract description 11
- 241000699660 Mus musculus Species 0.000 claims abstract description 10
- 230000006801 homologous recombination Effects 0.000 claims abstract description 8
- 238000002744 homologous recombination Methods 0.000 claims abstract description 8
- 210000002459 blastocyst Anatomy 0.000 claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 102000003839 Human Proteins Human genes 0.000 claims abstract description 4
- 108090000144 Human Proteins Proteins 0.000 claims abstract description 4
- 230000001939 inductive effect Effects 0.000 claims abstract description 3
- 210000004507 artificial chromosome Anatomy 0.000 claims abstract 6
- 230000035772 mutation Effects 0.000 claims description 49
- 210000004027 cell Anatomy 0.000 claims description 36
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical group C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 34
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims description 28
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims description 28
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 claims description 19
- 239000013598 vector Substances 0.000 claims description 17
- 101150050575 URA3 gene Proteins 0.000 claims description 12
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 12
- 102000046783 human APP Human genes 0.000 claims description 11
- 230000001717 pathogenic effect Effects 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 10
- 108700019146 Transgenes Proteins 0.000 claims description 8
- 108010021466 Mutant Proteins Proteins 0.000 claims description 7
- 102000008300 Mutant Proteins Human genes 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 6
- 229940035893 uracil Drugs 0.000 claims description 6
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 239000013605 shuttle vector Substances 0.000 claims description 4
- 230000012010 growth Effects 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims description 2
- SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 claims 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 abstract description 62
- 210000000349 chromosome Anatomy 0.000 abstract description 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 22
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 208000024827 Alzheimer disease Diseases 0.000 description 8
- 230000006798 recombination Effects 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 229930193140 Neomycin Natural products 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 229960004927 neomycin Drugs 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 108010078523 APP717 Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 235000015220 hamburgers Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000012256 transgenic experiment Methods 0.000 description 2
- OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 101710110830 Beta-agarase Proteins 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 238000011771 FVB mouse Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000824268 Kuma Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical compound CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 101150027734 cript gene Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001853 pulsed-field electrophoresis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15908493A | 1993-11-29 | 1993-11-29 | |
US08/159,084 | 1993-11-29 | ||
PCT/US1994/013604 WO1995014769A1 (fr) | 1993-11-29 | 1994-11-22 | Souris transgenique preparee a l'aide de chromosomes artificiels de levure et d'une recombinaison homologue |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09509046A true JPH09509046A (ja) | 1997-09-16 |
Family
ID=22571017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7515252A Pending JPH09509046A (ja) | 1993-11-29 | 1994-11-22 | トランスジェニックマウス |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPH09509046A (fr) |
WO (1) | WO1995014769A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004076661A1 (fr) * | 2003-02-27 | 2004-09-10 | Renascience Co., Ltd. | Production de cellules nerveuses pathologiques utilisant en combinaison un procede tres efficace d'induction de differenciation de nerf et des cellules souches embryonnaires knockin a mutation pathologique |
JP2007252217A (ja) * | 2006-03-20 | 2007-10-04 | Tottori Univ | 遺伝子導入非ヒト動物 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2042093C (fr) * | 1990-05-09 | 2002-12-24 | Gyula Hadlaczky | Lignee de cellules renfermant un exces de centromeres mammaliens |
DE69233109T2 (de) * | 1992-01-07 | 2004-05-19 | Elan Pharmaceuticals, Inc., San Francisco | Transgene tiermodelle fur alzheimer-krankheit |
EP0832205A1 (fr) * | 1995-06-07 | 1998-04-01 | Athena Neurosciences, Inc. | Procede d'identification de therapies de la maladie d'alzheimer a l'aide de modeles animaux transgeniques |
US6717031B2 (en) | 1995-06-07 | 2004-04-06 | Kate Dora Games | Method for selecting a transgenic mouse model of alzheimer's disease |
CA2222174A1 (fr) * | 1995-06-07 | 1996-12-19 | Athena Neurosciences, Inc. | Procede pour identifier une therapeutique de la maladie d'alzheimer a l'aide de modeles animaux transgeniques |
DE19530107A1 (de) * | 1995-08-16 | 1997-02-20 | Deutsches Krebsforsch | Verfahren zur gezielten Veränderung von Zell-DNA |
US6025155A (en) * | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US6077697A (en) | 1996-04-10 | 2000-06-20 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
WO1999009150A1 (fr) * | 1996-08-15 | 1999-02-25 | Bayer Corporation | Methode permettant d'introduire des modifications dans un gene |
AU4258097A (en) | 1996-09-06 | 1998-03-26 | Duke University | Methods for testing compounds for use as therapeutic antioxidants |
EP0912722A4 (fr) * | 1997-02-21 | 2001-12-05 | Michael Nehls | Procede servant a construire des vecteurs de recombinaison homologue pour une mutagenese dirigee |
US6090554A (en) * | 1997-10-31 | 2000-07-18 | Amgen, Inc. | Efficient construction of gene targeting vectors |
US6335185B1 (en) | 1998-02-03 | 2002-01-01 | University Technologies International Inc. | Bacteriophage vectors generated by bacteriophage/plasmid recombination |
US6503712B1 (en) | 2000-05-10 | 2003-01-07 | Amgen Inc. | Methods and compositions for preparing a genomic library for knockout targeting vectors |
WO2002044350A2 (fr) | 2000-11-28 | 2002-06-06 | Henkel Kommanditgesellschaft Auf Aktien | Nouvelle cyclodextrine-glucanotransferase (cgtase) issue de bacillus agaradherens (dsm 9948) et produits detergents et de nettoyage comprenant cette nouvelle cyclodextrine-glucanotransferase |
EP2527456B1 (fr) | 2004-10-22 | 2018-05-16 | Revivicor Inc. | Porcs transgéniques déficients en chaîne légère d'immunoglobuline endogène |
ES2316209B1 (es) * | 2005-12-02 | 2009-11-13 | Universidad Autonoma De Madrid | Modelo animal de enfermedad de alzheimer, procedimiento de obtencion y sus aplicaciones. |
EP2348827B1 (fr) | 2008-10-27 | 2015-07-01 | Revivicor, Inc. | Ongulés immunodéprimés |
-
1994
- 1994-11-22 JP JP7515252A patent/JPH09509046A/ja active Pending
- 1994-11-22 WO PCT/US1994/013604 patent/WO1995014769A1/fr active Application Filing
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004076661A1 (fr) * | 2003-02-27 | 2004-09-10 | Renascience Co., Ltd. | Production de cellules nerveuses pathologiques utilisant en combinaison un procede tres efficace d'induction de differenciation de nerf et des cellules souches embryonnaires knockin a mutation pathologique |
JP2007252217A (ja) * | 2006-03-20 | 2007-10-04 | Tottori Univ | 遺伝子導入非ヒト動物 |
JP4590638B2 (ja) * | 2006-03-20 | 2010-12-01 | 国立大学法人鳥取大学 | 家族性筋萎縮性側索硬化症(fals)発症するトランスジェニックマウス |
Also Published As
Publication number | Publication date |
---|---|
WO1995014769A1 (fr) | 1995-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09509046A (ja) | トランスジェニックマウス | |
Von Koch et al. | Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice | |
US6187992B1 (en) | Transgenic mouse having a disrupted amyloid precursor protein gene | |
JPH07508410A (ja) | 酵母人工染色体を有するトランスジェニック非ヒト動物の製造方法 | |
Moore et al. | Double replacement gene targeting for the production of a series of mouse strains with different prion protein gene alterations | |
EP0653154A2 (fr) | Animal transgènique pour la maladie d'Alzheimer | |
US5547841A (en) | In vitro method for screening for drugs that inhibit production or degradation of human A4-amyloid | |
US5814300A (en) | Gene-targeted non-human mammals deficient in the SOD-1 gene | |
JPH09507746A (ja) | Swedish変異を有するAPP対立遺伝子を含有するトランスジェニック動物 | |
Mallm et al. | Generation of conditional null alleles for APP and APLP2 | |
JP2023104002A (ja) | エクソンヒト化マウス | |
KR100646816B1 (ko) | 유전자 넉인 동물 | |
WO1996034097A1 (fr) | MAMMIFERES NON HUMAINS CIBLES PAR GENE PRESENTANT UN DEFICIT EN GENE SOD-1, EXPRIMANT UNE SEQUENCE Aβ HUMANISEE A MUTATION SUEDOISE DE FAD | |
AU782281B2 (en) | Transgenic animals as models for neurodegenerative disease | |
US5777194A (en) | Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation | |
EP0920495B1 (fr) | Modele animal transgenique pour la maladie d'alzheimer | |
CA2295861C (fr) | Methode de preparation d'un animal transgenique non-humain exprimant le p25 | |
US20060168673A1 (en) | Transgenic animals as models for neurodegenerative disease | |
KR100462180B1 (ko) | 알츠하이머병 병인 유전자로 형질전환된 동물 및 그 제조방법 | |
KR100699453B1 (ko) | 신경퇴행성 질환용 모델로서의 형질전환 동물 | |
EP1631661A2 (fr) | Animal transgenique comprenant une proteine precurseur amyloide presentant un site de clivage par la beta-secretase modifie | |
JP2000504202A (ja) | 本来のアミロイド前駆体タンパク質欠失トランスジェニック動物 | |
JPH08140527A (ja) | Treb5遺伝子欠損動物、及びその作出方法 | |
US20020157118A1 (en) | Genetically engineered animals containing null mutations in the neurofilament genes | |
WO1998014218A1 (fr) | MAMMIFERES ET CELLULES POSSEDANT UNE DISRUPTION HOMOZYGOTE DANS LE GENE RNase L ET PROCEDES ASSOCIES |